Canopy Growth Narrows Losses but Fails to Convince a Skeptical Market
Published on 06/18/2026 at 05:54 | Redaktion boerse-global.de
The numbers tell one story; the stock price tells another. Canopy Growth has slashed its annual net loss by more than 80%, with medical revenue surging in both Canada and international markets. Yet the equity trades just a whisker above its 52-week low of €0.75, at €0.83 — a level that suggests markets are reserving judgment until the company demonstrates it can turn regulatory tailwinds into durable profits.
For the fiscal year just ended, Canopy reported revenue of 284.6 million Canadian dollars, while the loss per share narrowed sharply to CAD 0.88 from CAD 5.56 a year earlier. The fourth quarter alone saw revenue climb to CAD 71.3 million, a near-10% year-over-year gain. More importantly, the per-share loss for the quarter fell to CAD 0.40, compared with CAD 1.43 in the same period last year. The improvement was driven by a 27% jump in Canadian medical sales and a robust 68% rise in the international segment, both of which underscore a shift in operational focus away from the recreational hype that once defined the sector.
The stock market’s response has been muted. At €0.83, Canopy Growth is trading nearly 60% below its 52-week high of €2.00 and remains underwater for the year by roughly 19%. Its 12-month decline extends to about 28%. The technical picture compounds the gloom: the shares sit comfortably below both the 50-day moving average of €0.94 and the 200-day average of €1.02, while the relative strength index at 35.4 points to persistent selling pressure rather than any turnaround momentum. A 30-day annualized volatility of almost 40% underscores just how much uncertainty surrounds the name.
Should investors sell immediately? Or is it worth buying Canopy Growth?
Regulation is the wildcard that keeps the narrative alive but unresolved. The US Department of Justice and the Drug Enforcement Administration have already reclassified certain FDA-approved cannabis products and state-licensed medical marijuana as Schedule III substances. But the broader federal rescheduling of marijuana remains locked in a formal rulemaking process that includes a public hearing, administrative review, and potential legal challenges. Canopy itself cites the uncertainty around US federal law, the implementation of medical rescheduling, and the strategic trajectory of its Canopy USA subsidiary as key variables for its outlook. This is a stock that has lived and died on legislative developments for years.
What has changed, however, is the market’s willingness to pay for mere proximity to reform. The sector’s maturation means investors now demand execution over possibility. Canopy still talks about a “strategic reset,” cost discipline, and building a stronger platform — the kind of language that once drew a premium. But the share price shows that rhetoric alone no longer suffices. The company’s sharply lower losses and medical segment growth are genuine steps forward, yet they have not triggered a re-rating. That suggests the market wants to see stable margins and disciplined capital allocation before it moves from watching to buying.
Canopy Growth thus remains caught in a waiting room of its own making. Half the story is positive: the operational repair is real, the medical business is gaining traction, and the US regulatory process still offers optionality. The other half is cautionary: the stock is down 19% year to date, the technicals are weak, and the company has not yet convinced investors it can thrive without leaning on the next Washington headline. For now, the bulls point to low expectations already priced in; the bears counter that execution — not a promise of reform — is the only thing that will get the shares moving higher.
Ad
Canopy Growth Stock: New Analysis - 18 June
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
